Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2021 April Clinical practice Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers Read more
2021 April Science Long-term follow-up of Ibrutinib monotherapy in symptomatic, previously treated patients with ... Read more
2021 April Pharma News Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin Lymphoma ... Read more
2021 April Clinical practice How should we use convalescent plasma therapies for the management of COVID-19? Read more
2021 March Editor's pick RELEVANT LITERATURE FOR YOUR DAILY PRACTICE SELECTED BY: GREGOR VERHOEF Read more
2021 March Science Clinical characteristics and outcomes of extranodal stage I DLBCL in the rituximab-Era Read more
Top
